Molecular fingerprint of precancerous lesions in breast atypical hyperplasia

Abstract

Objective To identify atypical hyperplasia (AH) of the breast by shell-isolated nanoparticle-enhanced Raman spectroscopy (SHINERS), and to explore the molecular fingerprinting characteristics of breast AH. Methods Breast hyperplasia was studied in 11 hospitals across China from January 2015 to December 2016. All patients completed questionnaires on women’s health. The differences between patients with and without breast AH were compared. AH breast lesions were detected by Raman spectroscopy followed by the SHINERS technique. Results There were no significant differences in clinical features and risk-related factors between patients with breast AH (n = 37) and the control group (n = 2576). Fifteen cases of breast AH lesions were detected by Raman spectroscopy. The main different Raman peaks in patients with AH appeared at 880, 1001, 1086, 1156, 1260, and 1610 cm−1, attributed to the different vibrational modes of nucleic acids, β-carotene, and proteins. Shell-isolated nanoparticles had different enhancement effects on the nucleic acid, protein, and lipid components in AH. Conclusion Raman spectroscopy can detect characteristic molecular changes in breast AH lesions, and may thus be useful for the non-invasive early diagnosis and for investigating the mechanism of tumorigenesis in patients with breast AH.

Diagnostic test of dynamic computed tomography in early gastrointestinal lymphoma and precancerous lesions

“…It is well known that the occurrence and development of malignant tumors is a long and complex process from normal epithelial cells to simple hyperplasia to atypical hyperplasia to carcinoma in situ to invasive cancer, precipitated by carcinogenic factors. The scientific consensus is that precancerous lesions begin with atypical hyperplasia ( 13 ), but the occurrence and development of cancer is not inevitable. Nevertheless, the vast majority of cancers have obvious precancerous lesions.…”